Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity.

C Latremouille; D Genevaz; M C Hu; O Schussler; N Goussef; C Mandet; P Bruneval; N Haeffner-Cavaillon; A Carpentier; D Glotz

doi:10.1046/j.1365-2249.1997.4591358.x

Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity.

Identifier:nobleid.org/w1/20260515/59CE2CB4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/59CE2CB4.svg?ark=w1%2F20260515%2F59CE2CB4)](https://nobleid.org/work/w1/20260515/59CE2CB4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity.

Identifier:nobleid.org/w1/20260515/59CE2CB4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/59CE2CB4.svg?ark=w1%2F20260515%2F59CE2CB4)](https://nobleid.org/work/w1/20260515/59CE2CB4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work